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NK cells are large granular lymphocytes that 
produce chemokines and cytokines and, so, par-
ticipate in the shaping of the inflammatory and 
adaptive immune response (Vivier et al., 2008; 
Yokoyama, 2008). They are also an important 
part of the innate immune system as they di-
rectly kill transformed and virally infected cells 
(Smyth et al., 2002; Lanier, 2005; Yokoyama, 
2008). NK cells survey potential targets for ex-
pression of MHC class I via cell surface inhibi-
tory receptors (Parham, 2005). Engagement of 
these inhibitory receptors by MHC class I pre-
vents NK cell activation, thereby protecting the 
target cells from NK cell attack. NK cell effector 
function thus arises in part from recognition 
of “missing self” (Kärre et al., 1986). The dis-
covery  of  NK-activating  receptors,  including 
the natural cytotoxicity receptor (NCR) family, 
NKG2D, and DNAM-1, revealed that in addi-
tion to an absent inhibitory signal, activating sig-
nals were also necessary for NK activation and 
tumor cell lysis (Pende et al., 1999; Moretta 
et al., 2001). The NCR family includes NKp46 
(NCR1, CD335), NKp44 (NCR2, CD336), and 
NKp30 (NCR3, CD337). NCR association with 
CD3, KARAP/DAP12, and Fcr immuno-
receptor tyrosine-based activation motif–bearing 
transducing polypeptides is reminiscent of the 
architecture of other pivotal immune receptor 
complexes, such as the T, B, and Fc receptors, 
and makes them very potent activating receptors 
(Bryceson et al., 2006). Although multiple ligands 
for NKG2D and DNAM-1 have been identi-
fied (Bottino et al., 2005), tumor cell surface 
ligands for the NCR family have remained 
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Cancer development is often associated with the lack of specific and efficient recognition 
of tumor cells by the immune system. Natural killer (NK) cells are lymphocytes of the 
innate immune system that participate in the elimination of tumors. We report the identi-
fication of a tumor cell surface molecule that binds NKp30, a human receptor which trig-
gers antitumor NK cell cytotoxicity and cytokine secretion. This previously unannotated 
gene belongs to the B7 family and, hence, was designated B7-H6. B7-H6 triggers NKp30-
mediated activation of human NK cells. B7-H6 was not detected in normal human tissues 
but was expressed on human tumor cells, emphasizing that the expression of stress-induced 
self-molecules associated with cell transformation serves as a mode of cell recognition in 
innate immunity.
© 2009 Brandt et al.  This article is distributed under the terms of an Attribu-
tion–Noncommercial–Share Alike–No Mirror Sites license for the first six months 
after the publication date (see http://www.jem.org/misc/terms.shtml). After six 
months it is available under a Creative Commons License (Attribution–Noncom-
mercial–Share Alike 3.0 Unported license, as described at http://creativecommons 
.org/licenses/by-nc-sa/3.0/).
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ability of NK-92 cells to kill K562 targets (Fig. 1 A). Collec-
tively,  these  experiments  revealed  K562  cells  and  soluble 
NKp30-Fc proteins as practicable tools for the identification 
of a cell surface ligand for NKp30.
A proteomic approach was used to search for this counter 
structure. Biotinylated NKp30-Fc was used as a probe in chemi-
cal cross-linking studies to K562 cells. Proteins cross-linked 
to the NKp30-Fc protein were precipitated, separated by gel 
electrophoresis, and subjected to in-gel tryptic digestion. The 
resulting peptides were analyzed by mass spectrometry. Sub-
stractive proteomic analysis was used to identify candidate 
NKp30 binding proteins that were unique to K562 cell ly-
sates and were identified by two or more peptides. Two of 
these candidates were predicted to have transmembrane do-
mains, and their complementary DNAs were obtained for 
subsequent studies. A recombinant Fc fusion form of one of 
these candidates (hypothetical protein DKFZp686O24166) 
gave specific binding to soluble NKp30 as judged by surface 
plasmon resonance (SPR) experiments (Fig. 2 A). NKp30 
interaction with DKFZp686O24166 was inhibited by anti-
NKp30 mAbs (1849 and AZ20) that block NKp30-depen-
dent NK cell activation (Fig. 2 A).
DKFZp686O24166 codes for a 454-aa-long type I trans-
membrane protein (51 kD predicted molecular mass) with 
an intracytoplasmic domain that is homologous to GAG 
polyprotein.  Interestingly,  this  intracytoplasmic  domain 
also contains various signaling motifs, such as an immuno-
receptor tyrosine-based inhibition motif (SaYtpL), an SH2 
(Src homology 2)-binding domain (YqlQ), and an SH3-
binding motif (PdaPilPvsP), suggesting the possibility that 
DKFZp686O24166  could  provide  signals  when  engaged 
(Fig. 2 B). A BLAST query revealed that two of the most 
related proteins are members of the B7 family (B7-H1 and 
B7-H3). Like all known B7 family members (B7.1, B7.2, 
elusive, hindering a complete understanding of their role in 
tumor surveillance. For example, despite the involvement of 
NKp30 in the lysis of various tumor cell lines and primary tu-
mor cells, including carcinomas, neuroblastomas, and myeloid 
and lymphoblastic leukemias (Pende et al., 1999, 2002; Sivori 
et al., 2000; Castriconi et al., 2004; Nowbakht et al., 2005; 
Byrd et al., 2007), its tumor ligands are still unknown. The 
HLA–B-associated transcript 3 (BAT3) and the pp65 proteins 
have been shown to bind NKp30, but they do not correspond 
to tumor cell surface ligands because pp65 is a human cyto-
megalovirus tegument protein (Arnon et al., 2005) and BAT3 
is a nuclear protein released upon heat shock treatment (Pogge 
von Strandmann et al., 2007). In this paper, we report that 
human NKp30 directly interacts with a novel member of the 
B7 family that we refer to as B7-H6. Using NKp30 reporter 
cells, human IL-2–driven NK cell lines, and freshly isolated 
human blood NK cells, we show that the expression of B7-H6 
on tumor cells induces NKp30-dependent cell activation and 
cytotoxicity. Furthermore, B7-H6 was absent from all normal 
cells tested but was selectively expressed on tumor cells. These 
results show the first instance of a tumor-specific B7 family 
member that can directly trigger NK cell activation.
RESULTS aNd dISCUSSION
Identification of B7-H6 as a ligand for NKp30
The human NK-92 cell line expresses surface NKp30 (not 
depicted) and mediates killing of the human chronic myelog-
enous leukemia cell line K562 (Fig. 1 A). To search for mol-
ecules  that  bind  to  NKp30  and  trigger  NKp30-mediated 
cytolysis in NK cells, we generated soluble NKp30-Fc fusion 
proteins. Soluble NKp30-Fc proteins bound to K562 cells, 
and this binding was abolished by blocking anti-NKp30mAb 
(AZ20)  but  not  by  blocking  control  anti-NKp46  mAb 
(BAB281; Fig. 1 B). In addition, soluble NKp30 reduced the 
Figure 1.  Soluble NKp30-Fc inhibits NK-92 cytolysis and binds K562 cells. (A) Soluble NKp30-Fc inhibited the killing of K562 cells by NK-92 cells. 
A 4-h cytoxicity assay was performed in the presence (thin line) or absence (bold line) of 2 µg/ml NKp30-Fc. Data indicate the mean of triplicates ± SD 
and are representative of three independent experiments. (B) Soluble NKp30-Fc binds K562. The binding of NKp30-Fc to K562 cells was measured by flow 
cytometry in the presence of blocking anti-NKp30 F(ab)2 mAb (AZ20, IgG1) or a negative control anti-NKp46 F(ab)2 mAb (BAB281, IgG1). Data are repre-
sentative of at least three independent experiments.JEM VOL. 206, July 6, 2009  1497
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Figure 2.  Characterization of B7-H6. (A) Direct interaction of B7-H6 with NKp30 using SPR. The data show binding of soluble DKFZp686O24166-Fc 
to immobilized NKp30-Fc in the presence or absence of blocking anti-NKp30 mAb (1849 and AZ20). Data are representative of three independent experi-
ments. (B) Protein sequence encoded by the B7-H6 gene. Predicted signal peptide, IgV, IgC, and transmembrane domains are indicated. (C) Schematic 
representation of the B7-H6 and the NKp30 gene orgnaization compared with members of the B7 and the CD28 families, respectively. Each domain is 
represented as a box and is encoded by exons that are separated by phase 0, 1, or 2 introns as indicated. The scheme refers to the “canonical” sequence as 
defined by www.uniprot.org. (D) The data show SPR experiments using soluble B7-H1-Fc, B7-H3-Fc, 4IgB7-H3-Fc, B7-H6-Fc, and B7-DC-Fc and immobi-
lized NKp30-Fc. RU, relative units. Data are representative of two independent experiments.1498 B7-H6 IS A TUMOR CELL LIGAND FOR NKp30 | Brandt et al.
Functional significance of B7-H6 surface expression
The IL-2–producing DO11.10 mouse T cell hybridoma ex-
pressing a chimeric receptor formed by NKp30 extracellular 
domain fused to CD3 (DOMSP30 cells; Schleinitz et al., 
2008) was used as a reporter cell system to evaluate whether 
B7-H6 was able to induce signaling directly through NKp30. 
DOMSP30 reporter cells were activated by plate-bound anti-
NKp30 mAbs, which is in contrast to DOMSP46 reporter 
cells expressing a NKp46-CD3 chimeric receptor which 
were selectively responsive to NKp46 cross-linking (Fig. 3 A). 
DOMSP30 reporter cells produced IL-2 in the presence of 
P815 expressing B7-H6 (P815.B7-H6), whereas P815 ex-
pressing a control protein (P815.B7-H1) failed to elicit such 
a response (Fig. 3 B). Parental DO11.10 cells and DOMSP46 
reporter cells were unresponsive to P815.B7-H6 cells (Fig. 3 B). 
IL-2 production was markedly reduced by addition of either 
blocking  anti-NKp30  mAb  F(ab)2  or  affinity-purified   
B7-H6 antiserum (Fig. 3 C). No inhibition was observed with 
blocking anti-NKp46 mAb F(ab)2 controls. Together, these 
results show that B7-H6 engagement of the NKp30/CD3 
chimera leads to cell activation. To further examine the func-
tional significance of the interaction of NKp30 with B7-H6, 
parental P815 cells and P815.B7-H6 cells were used as targets 
for the NK-92 cell line (Fig. 3 D). Although parental P815 
cells were lysed poorly by NK-92 cells, P815.B7-H6 cells 
were lysed effectively (Fig. 3 D). This susceptibility to cytol-
ysis was impaired by addition of soluble NKp30-Fc but not 
by addition of soluble B7-H3-Fc control proteins (Fig. 3 D). 
P815.B7-H6 cells were also lysed by IL-2–activated primary 
human NK cells and this cytotoxicity was blocked by addi-
tion of soluble NKp30-Fc (Fig. 3 E). These data indicate that 
B7-H6 expression on tumor cells can confer sensitivity to 
NKp30-specific cytolysis. Consistent with these data, freshly 
isolated blood NK cells were activated by P815.B7-H6 cells 
but not by P815.B7-H1 cells, as assessed by cell surface ex-
pression of CD107a (LAMP-1) and intracytoplasmic detec-
tion of IFN- (Fig. 3 F). That a tumor ligand for the activating 
receptor NKp30 was a member of the B7 family was an un-
expected finding. Indeed, recent studies have shown that hu-
man and rodent cancer cells up-regulate expression of B7 
molecules, such as B7-H1, 4IgB7-H3, and B7-H4, but this 
expression has been proposed to contribute to tumor immune 
evasion by engaging inhibitory receptors (Castriconi et al., 
2004; Zou and Chen, 2008).
Cellular distribution of B7-H6
Having established that B7-H6 was a functionally relevant 
counter structure for NKp30, we next analyzed its expression 
pattern. Quantitative reverse transcription polymerase chain 
reaction analysis of B7-H6 messenger RNA (mRNA) on a 
normal tissue array showed no detectable expression in any of 
the 48 normal tissues assayed (unpublished data). This paucity 
of B7-H6 mRNA in normal tissues was consistent with mi-
croarray analysis of the gene (Shyamsundar et al., 2005; and 
not depicted). Collectively with the fact that few expressed 
sequence tags for B7-H6 have been identified, these data suggest 
B7-DC, and B7-H1 to B7-H4/B7h.5; Zou and Chen, 2008), 
DKFZp686O24166 has two Ig domains with adjacent phase 1 
introns in the extracellular region (Fig. 2 C). TPSNR (tapasin-
related protein), PVR (poliovirus receptor; CD155), CADM3 
(cell adhesion molecule 3), and CXADR (Coxsackie virus and 
adenovirus receptor) also showed amino acid similarity, but 
their gene and predicted domain organization were different 
from those of DKFZp686O24166. Further protein homology 
analysis revealed that the percentage of DKFZp686O24166 
identity with other B7 family members is comparable to the 
percentages of identity observed within this group of distantly 
related molecules (Table S1). In addition, a BLAST query re-
vealed that the closest homologue of NKp30 was CTLA-4, a 
receptor for B7.1 and B7.2. Like other members of the CD28 
family, NKp30 has a single predicted IgV domain in its extra-
cellular region, whereas nearly all other Ig domain–contain-
ing immunoreceptors have multiple Ig domains. Moreover, 
the gene structure of the extracellular region is identical be-
tween NKp30 and all other CD28 family genes. Specifically, 
there is an exon containing the leader peptide, followed by 
a phase 1 intron, then the exon containing the IgV domain, 
and another phase 1 intron, followed by a short exon con-
taining the transmembrane region (Fig. 2 C). The only other 
proteins identified to date that have this exact gene struc-
ture are the known members of the CD28 family including 
CD28, CTLA-4 (CD152), BTLA (CD272), ICOS (CD278), 
and PD-1 (CD279). NKp30 could thus be considered as a 
member of the CD28 family whose members do not share 
significant sequence similarity to each other but do share a 
similar gene structure. Thus, because DKFZp686O24166 had 
a gene and protein structure similar to that of other members 
of the B7 family, two of its closest homologues were members 
of that group, and its putative counter structure, NKp30, is 
related to the CD28 family, we designated the gene B7-H6. 
B7-H6 was present in genomic clone AC124798 (available at 
GenBank/EMBL/DDBJ) which maps to chromosome region   
11p15.1. A short region corresponding to the first exon of hu-
man B7-H6 was found in the mouse genome (near bp 47,000 
of AC146610.4, available at GenBank/EMBL/DDBJ), but a 
full-length gene sequence was not evident. This mouse exon 
appears to have intact splice sites at either end, but no other 
nearby regions of the mouse genome have other exons related 
to B7-H6. Finally, this isolated exon from the mouse does not 
have any related ESTs from mouse libraries, and we conclude 
that the Mus musculus genome is missing a full-length gene 
corresponding to human B7-H6.
Given the structure of B7-H6, we also tested it for possi-
ble interactions with the other known CD28 family members 
but only observed binding with soluble NKp30 (unpublished 
data). Moreover, B7-H6 did not bind to other NK-activating 
receptors including NKp44, NKp46, and NKG2D (unpub-
lished data). No binding of NKp30-Fc to B7.1, B7-DC, 
B7-H3, 4IgB7-H3, or B7-H1 could be detected (Fig. 2 D). 
These results indicated that the extracellular domain of NKp30 
directly and selectively interacts with the extracellular do-
main of B7-H6, a novel member of the B7 family.JEM VOL. 206, July 6, 2009  1499
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N-glycosylation sites. It thus remains to be tested whether 
the glycosylation of B7-H6 might contribute to its interaction 
with NKp30, although we could not alter DOMSP30 cell 
activation by addition of heparan sulfate (unpublished data).
Recent reports have revealed that the induction of stress-
induced self is a common mechanism that leads to the initia-
tion of innate immune response (Raulet, 2003). In preliminary 
experiments, no induction of B7-H6 cell surface expression 
was detected under various conditions of cellular stress such as 
heat shock, genotoxicity ( radiation or sodium butyrate treat-
ment), or inhibition of proteasomal degradation (MG-132 
treatment). In contrast, B7-H6 was expressed at the surface of 
several tumor cell lines including T and B lymphomas, my-
eloid leukemias, melanomas, carcinomas, and large T SV40 
antigen-transformed cells (Fig. 4 A). In a broader survey, 
B7-H6 expression was detected on 24 of 119 cancer cell lines 
(unpublished data). The surface expression of B7-H6 was also 
tested on primary tumor blood and bone marrow cells ob-
tained at diagnosis from 43 individuals with a variety of hema-
tological malignancies, including acute nonlymphoblastic 
leukemia (ANLL; n = 20), acute lymphoblastic leukemia 
(ALL; n = 11), and non-Hodgkin’s and Hodgkin’s lymphoma 
(n = 12). B7-H6 expression was observed on circulating 
that B7-H6 is not abundantly expressed in any normal tissues 
examined. This was also supported by the failure to detect 
B7-H6 at the surface of freshly isolated PBMCs from all do-
nors tested using affinity-purified B7-H6 antiserum (Fig. 4 A) 
or mAbs directed against B7-H6 (not depicted). Moreover, 
no B7-H6 cell surface staining was observed on phytohemag-
glutinin-stimulated PBMCs (unpublished data). It is of note 
that although NKp30 has a role in NK cell–DC cross-talk 
(Ferlazzo et al., 2002; Vitale et al., 2005), no B7-H6 mRNA 
or protein expression was detected when assaying resting or 
activated  DCs  generated  from  PBMCs  with  IL-4  and   
GM-CSF (unpublished data). It is therefore possible that BAT3 
serves as a ligand for NKp30 on DCs (Simhadri et al., 2008), 
indicating that NKp30 might interact with several ligands, as 
this is the case for NKG2D and DNAM-1 (Raulet, 2003; 
Soriani et al., 2009). Along this line, it has been shown that 
NKp30 and other NCRs can recognize heparan sulfate 
(Hecht et al., 2009). Heparan sulfates are found in the com-
monest linkage type with xylose O-glycosidically linked to 
serine. No potential O-glycosylation sites could be found 
in B7-H6. There are also studies where heparan sulfate has 
been generated as N-glycans (Sundblad et al., 1988), and the 
extracytoplasmic domain of B7-H6 harbors nine potential 
Figure 3.  B7-H6 cell surface expression triggers NKp30-dependent cell activation. (A–C) DO.11.10, DOMSP30, and DOMSP46 cells were stimu-
lated using the indicated plate-bound mAbs (A) or P815.B7-H1 versus P815.B7-H6 cells in the absence (B) or presence of indicated F(ab)2 mAbs or B7-H6 
mouse antiserum (C). Data indicate the mean of triplicates + SD and are representative of three independent experiments. (D and E) NK-92 cells (D) and 
IL-2–stimulated primary NK cells (E) were used in a cytolytic assay against P815 cells (thin line) or P815.B7-H6 cells (bold line). Soluble NKp30-Fc (thin 
dashed line) and control Fc-fusion protein (B7-H3-Fc; bold dashed line) were used at 2 µg/ml. (F) Freshly isolated primary blood NK cells in PBMCs were 
tested for their activation induced by P815.B7-H1 or P815.B7-H6 cells in the presence or absence of anti-NKp30 F(ab)2 mAbs or control mouse Ig (mIg). 
500,000 PBMCs were added to 100,000 tumor cells. The fraction of reactive NK cells (percentage of responding NK cells) was assessed by adding the per-
centage of CD107+IFN-, CD107+IFN-+, and CD107IFN-+ NK cells. Data are representative of three independent experiments. Error bars indicate SD. 
Statistical analysis was performed using a Mann-Whitney U test. *, P < 0.05.1500 B7-H6 IS A TUMOR CELL LIGAND FOR NKp30 | Brandt et al.
Figure 4.  B7-H6 is not detected on blood cells but is expressed on tumor cells. (A and B) Assessment of B7-H6 cell surface staining on PBMCs, 
P815 cell transfectants, and tumor cells was performed by flow cytometry using anti–B7-H6 mouse antiserum. (C) NKp30-Fc cell surface staining on JEM VOL. 206, July 6, 2009  1501
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on a Magic C18AQ (Michrom Bioresources, Inc.) 3-µm 200-Å resin packed 
into 10 cm of 50 µm of fused silica. Eluted peptides were analyzed by nano–
liquid chromatography tandem mass spectrometry using an ion-trap mass spec-
trometer (Thermo Fisher Scientific) interfaced with nanoflow RP-HPLC. 
Proteins were identified by an X!Tandem search of peptide mass spectra 
against the human and mouse IPI database for K562 cells and BaF3 cells 
(used as a negative control), respectively.
Affinity-purified  B7-H6  antiserum  production  and  purification. 
Female BALB/c mice (Charles River Laboratories) were immunized by 
subcutaneous injection with purified recombinant human B7-H6 tetramer 
in combination with Emulsigen-P adjuvant (MVP Laboratories, Inc.) as per 
the manufacturer’s instructions. Mice were boosted subcutaneously every 
2 wk over a 9-wk period. Serum from mice challenged with B7-H6 tetramer 
was pooled and affinity purified on B7-H6-Fc protein coupled to CNBr-
activated Sepharose 4B (GE Healthcare). Specificity of the eluted antiserum 
was confirmed by FACS analysis on B7-H6–transfected P815 cells compared 
with untransfected P815.
SPR. SPR analysis was performed on a Biacore T100 apparatus (GE Health-
care) at 25°C. In all Biacore experiments, HBS-EP+ buffer served as running 
buffer and sensorgrams were analyzed with Biaevaluation 4.1 and Biacore T100 
Evaluation software. Recombinant protein was immobilized covalently to car-
boxyl groups in the dextran layer of a Biacore Sensor Chip CM5. Competition 
assays were performed in acidic buffer, pH 5.6. Flow rate was set to 10 µl/min. 
mAbs were injected at 50 µg/ml before the injection of B7-H6-Fc.
Primary NK cell preparation, culture, and activation. PBMCs were 
isolated from healthy volunteer donors using Ficoll-Paque Plus (GE Health-
care) density centrifugation. For CD107 mobilization and IFN- produc-
tion, PBMCs were incubated 4 h at 37°C in the presence of 5 µM monensin 
(Sigma-Aldrich), CD107 mAb, and the indicated stimuli. Cells were then 
washed in PBS with 2 mM EDTA and stained for extracellular markers. 
Thereafter, cells were fixed with 2% paraformaldehyde and permeabilized 
using Perm/Wash buffer (BD). NK cells were electronically gated as 
CD3CD56+. Intracellular IFN- was detected using APC–IFN- (BD).
Immunofluoresence and flow cytometry. Mouse isotype control anti-
bodies (mIg) consisted of an equimolar mixture of commercially available 
isotype control mouse IgG1, IgG2a, IgG2b, and IgM (BD). Human isotype 
control antibodies (hIg) were a mixture of human Ig (TEGELIN, Labora-
toire français du Fractionnement et des Biotechnologies). For NKp30-hFc 
stainings, 5 µg/ml NKp30-hFc was mixed to 5 µg/ml of PE-conjugated 
anti–human Ig (Jackson ImmunoResearch Laboratories) for 1 h at 4°C be-
fore incubation with cells for 30 min at 4°C. Fluorescent stainings were ana-
lyzed on a FACSCanto (BD) using the FlowJo software (Tree Star, Inc.).
DOMSP30 assay. DOMSP30 and DOMSP46 reporter cell lines were gen-
erated by transduction of the DO.11.10 T cell hybridoma with retroviral 
particles encoding a chimeric protein in which the intracytoplasmic domain 
of mouse CD3 was fused either to the extracellular portion of NKp30 
(DOMSP30) or NKp46 (DOMSP46). Engagement of these chimeric pro-
teins at the cell surface triggers IL-2 secretion. DOMSP30, DOMSP46, or 
DO.11.10 (30,000 cells/well in 96-well plates) were incubated on anti-
NKp30 or anti-NKp46 mAb-coated plates or with tumor cell lines (30,000 
cells/well in 96-well plates). After 20 h, cell supernatants were assayed for 
the presence of mouse IL-2 in a standard CTLL-2 survival assay using Cell 
Titer-Glo Luminescent Cell Viability Assay (Promega).
tumor cells from three patients with ANLL, two patients 
with T-ALL, and one patient with marginal zone lymphoma 
(Fig. 4 B). B7-H6 cell surface expression correlated with the 
binding of NKp30-Fc to the cell surface and with the capacity 
of tumor cell lines to activate resting blood NK cells (Fig. 4, 
C and D). Collectively, these data indicated that B7-H6 is a 
major NKp30 ligand on tumor cells of various origins, includ-
ing K562, a prototypical model of tumor NK cell target.
The absence of B7-H6 mRNA in normal tissues, coupled 
with its relative abundance among tumor cells, indicates that 
its expression is up-regulated by tumor transformation. These 
findings highlight the role of tumor-induced self-molecules 
in alerting innate immunity and prompt further investigations 
on whether B7-H6 expression correlates with tumor prog-
nosis in a large cohort of patients and on the regulation of 
B7-H6 expression.
Materials and Methods
Soluble recombinant proteins. In-frame fusion proteins of the extracellular 
domains of NKp30 (aa 1–132) or of B7-H6 (aa 1–267) and an effector-nega-
tive version of the mouse IgG2a Fc region (aa 216 through the C-terminal 
lysine) were constructed in a mammalian expression vector (NKp30-mFc). 
Secreted Fc fusion proteins from stable Chinese hamster ovary transfec-
tants were purified by affinity chromatography on Protein A Sepharose (GE 
Healthcare). For the generation of mouse Fc fusion protein, mutations in 
mIgG2a were introduced as follows. The hinge residue corresponding to EU 
Index position 219 was changed from Gly in the wild-type 2a sequence to 
Ser to mimic the amino acid substitution made in human Fc4, Fc5, and 
Fc10. For CH2, one amino acid substitution was introduced in mFc2 relative 
to mouse wild-type 2a at EU Index position 235 (Leu to Glu) to inactivate 
binding to FcRI and FcRII (Duncan et al., 1988; Zheng et al., 1999). 
Three additional changes were made at the complement C1q binding site to 
reduce complement fixation at EU Index positions 318, 320, and 322 (Duncan 
and Winter, 1988; Duncan et al., 1988). A soluble recombinant NKp30 
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